[go: up one dir, main page]

WO2001000188A3 - Tetrahydrochinolinyl-6-methyldihydrothiadiazinon-derivate ind ihre verwendung zur prophylaxe und/oder behandlung von anämien - Google Patents

Tetrahydrochinolinyl-6-methyldihydrothiadiazinon-derivate ind ihre verwendung zur prophylaxe und/oder behandlung von anämien Download PDF

Info

Publication number
WO2001000188A3
WO2001000188A3 PCT/EP2000/005571 EP0005571W WO0100188A3 WO 2001000188 A3 WO2001000188 A3 WO 2001000188A3 EP 0005571 W EP0005571 W EP 0005571W WO 0100188 A3 WO0100188 A3 WO 0100188A3
Authority
WO
WIPO (PCT)
Prior art keywords
tetrahydroquinolinyl
methyldihydrothiadiazinone
derivatives
preventing
treating anaemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2000/005571
Other languages
English (en)
French (fr)
Other versions
WO2001000188A2 (de
Inventor
Juergen Stoltefuss
Gabriele Braeunlich
Michael Loegers
Carsten Schmeck
Ulrich Nielsch
Martin Bechem
Christian Gerdes
Michael Sperzel
Klemens Lustig
Werner Stuermer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Priority to CA002376891A priority Critical patent/CA2376891A1/en
Priority to JP2001505898A priority patent/JP2003503345A/ja
Priority to US10/018,928 priority patent/US6699857B1/en
Priority to EP00947850A priority patent/EP1196173A2/de
Priority to AU61504/00A priority patent/AU6150400A/en
Publication of WO2001000188A2 publication Critical patent/WO2001000188A2/de
Publication of WO2001000188A3 publication Critical patent/WO2001000188A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Die Erfindung betrifft das Gebiet der Erythropoese. Insbesondere wird die Verwendung von Tetrahydrochinolinyl-6-methyldihydrothiadiazinonen der allgemeinen Formel (I) zur Prophylaxe und/oder Behandlung von Anämien beschrieben. Des weiteren werden neue Tetrahydrochinolinyl-6-methyldihydrothiadiazinon-Derivate und ihre Herstellung beschrieben.
PCT/EP2000/005571 1999-06-29 2000-06-16 Tetrahydrochinolinyl-6-methyldihydrothiadiazinon-derivate ind ihre verwendung zur prophylaxe und/oder behandlung von anämien Ceased WO2001000188A2 (de)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002376891A CA2376891A1 (en) 1999-06-29 2000-06-16 Tetrahydroquinolinyl-6-methyldihydrothiadiazinone derivatives and use thereof
JP2001505898A JP2003503345A (ja) 1999-06-29 2000-06-16 テトラヒドロキノリニル−６−メチルジヒドロチアジアジノン誘導体およびそれらの使用
US10/018,928 US6699857B1 (en) 1999-06-29 2000-06-16 Tetrahydroquinolinyl 6-methyldihydrothiadiazinone derivatives and use thereof
EP00947850A EP1196173A2 (de) 1999-06-29 2000-06-16 Tetrahydrochinolinyl-6-methyldihydrothiadiazinon-derivate und ihre verwendung zur prophylaxe und/oder behandlung von anämien
AU61504/00A AU6150400A (en) 1999-06-29 2000-06-16 Tetrahydroquinolinyl-6-methyldihydrothiadiazinone derivatives and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19929785.1 1999-06-29
DE19929785A DE19929785A1 (de) 1999-06-29 1999-06-29 Tetrahydrochinolinyl-6-methyldihydrothiadiazinon-Derivate und ihre Verwendung

Publications (2)

Publication Number Publication Date
WO2001000188A2 WO2001000188A2 (de) 2001-01-04
WO2001000188A3 true WO2001000188A3 (de) 2001-03-22

Family

ID=7912943

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/005571 Ceased WO2001000188A2 (de) 1999-06-29 2000-06-16 Tetrahydrochinolinyl-6-methyldihydrothiadiazinon-derivate ind ihre verwendung zur prophylaxe und/oder behandlung von anämien

Country Status (7)

Country Link
US (1) US6699857B1 (de)
EP (1) EP1196173A2 (de)
JP (1) JP2003503345A (de)
AU (1) AU6150400A (de)
CA (1) CA2376891A1 (de)
DE (1) DE19929785A1 (de)
WO (1) WO2001000188A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102325531B (zh) * 2008-12-19 2014-04-02 健泰科生物技术公司 化合物和使用方法
CN103958508B (zh) 2011-10-14 2019-02-12 艾伯维公司 用于治疗癌症以及免疫与自身免疫性疾病的细胞凋亡诱导剂
US8889675B2 (en) 2011-10-14 2014-11-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916128A (en) * 1987-06-06 1990-04-10 Merck Patent Gesellschaft Mit Beschrankter Haftung Thiadiazinones
US4987121A (en) * 1988-05-27 1991-01-22 Center For Innovative Technology Erythropoietic factor
US5137885A (en) * 1990-12-21 1992-08-11 Merck Patent Gesellschaft Mit Beschraenkter Haftung Thiadiazinones
US5188828A (en) * 1990-11-08 1993-02-23 Brigham And Women's Hospital Interleukin-6 to stimulate erythropoietin production
US5206363A (en) * 1991-09-02 1993-04-27 Merck Patent Gesellschaft Mit Beschrankter Haftung Process for the resolution of enantiomers of 5-heteroaryl-1,3,4-thiadiazinones
US5643938A (en) * 1992-06-10 1997-07-01 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compounds for the treatment of anemia
DE19904391A1 (de) * 1999-02-04 2000-08-10 Bayer Ag Pyrazol-Alkylamide

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4230755A1 (de) 1992-09-14 1994-03-17 Schering Ag Verwendung von PDE-Inhibitoren bei der Behandlung von Nieren- und Ureter-Erkrankungen
DE4338948A1 (de) 1993-11-15 1995-05-18 Carlen Judith Verwendung von PDE-Inhibitoren bei der Behandlung erektiler Dysfunktionen
DE19500558A1 (de) 1995-01-11 1996-07-18 Merck Patent Gmbh 3-Alkoxycarbonyl-thiadiazinone

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916128A (en) * 1987-06-06 1990-04-10 Merck Patent Gesellschaft Mit Beschrankter Haftung Thiadiazinones
US4987121A (en) * 1988-05-27 1991-01-22 Center For Innovative Technology Erythropoietic factor
US5188828A (en) * 1990-11-08 1993-02-23 Brigham And Women's Hospital Interleukin-6 to stimulate erythropoietin production
US5137885A (en) * 1990-12-21 1992-08-11 Merck Patent Gesellschaft Mit Beschraenkter Haftung Thiadiazinones
US5206363A (en) * 1991-09-02 1993-04-27 Merck Patent Gesellschaft Mit Beschrankter Haftung Process for the resolution of enantiomers of 5-heteroaryl-1,3,4-thiadiazinones
US5643938A (en) * 1992-06-10 1997-07-01 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compounds for the treatment of anemia
DE19904391A1 (de) * 1999-02-04 2000-08-10 Bayer Ag Pyrazol-Alkylamide

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SCHWINGER R H G ET AL: "Enantioselective Ca-2+-sensitizing effects of EMD 53998, EMD 57033 and EMD 57439 in human myocardium.", EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, vol. 24, no. SUPPL. 2, 1994, 28th Annual Scientific Meeting of the European Society for Clinical Investigation;Toledo, Spain; April 20-23, 1994, pages A5, XP000972326, ISSN: 0014-2972 *
WAUGH WILLIAM H ET AL: "Evidence that L-arginine is a key amino acid in sickle cell anemia - A preliminary report.", NUTRITION RESEARCH, vol. 19, no. 4, April 1999 (1999-04-01), pages 501 - 518, XP000972387, ISSN: 0271-5317 *

Also Published As

Publication number Publication date
US6699857B1 (en) 2004-03-02
CA2376891A1 (en) 2001-01-04
AU6150400A (en) 2001-01-31
JP2003503345A (ja) 2003-01-28
DE19929785A1 (de) 2001-01-04
WO2001000188A2 (de) 2001-01-04
EP1196173A2 (de) 2002-04-17

Similar Documents

Publication Publication Date Title
WO2002008194A8 (de) Acridin-derivate und deren verwendung als arzneimittel
WO1999054326A8 (de) Dihydropyrimidine
WO1999002497A3 (en) Pyridine derivatives
WO2002008190A3 (de) Neue heteroaryl-derivate und deren verwendung als antitumormittel
HK1047283A1 (zh) 以四羥基喹啉葎基(tetrahydroquinolinyl)、芳基或雜芳基和烷基取代的具有視網膜樣的生物活性的胺類
WO2001066564A3 (en) Gamma-secretase inhibitors
CA2352505A1 (en) Epothilone derivatives and their use as antitumor agents
WO2000035919A3 (en) Quinoline derivatives
MXPA02001498A (es) Derivados de 3(5)-amino-pirazol, procedimiento para la preparacion de los mismos y usos como agentes antitumorales.
MXPA02001497A (es) Derivados de 3-(5)-ureido-pirazol, procedimiento para su preparacion y sus uso como agentes antitumorales.
TW289020B (de)
CA2297911A1 (en) Substituted 6-phenylphenanthridines
WO2000071507A3 (en) INHIBITORS OF FACTOR Xa
CA2343236A1 (en) 4,4-biarylpiperidine derivatives
IL129592A0 (en) 5-HT1f agonists
AU6989800A (en) Diamino-1,2,4-triazole-carboxylic and derivatives as gsk-3 inhibitors
WO2001047928A3 (de) Imidazo 1,3,5 triazinone und ihre verwendung
CA2388476A1 (en) Bicyclic imidazo-5-yl-amine derivatives
CA2262566A1 (en) Benzamidine derivatives and the use thereof as medicaments with ltb4-antagonistic effect
WO2002010152A3 (de) Neue indolderivate und deren verwendung als arzneimittel
WO2002016340A8 (fr) Aminoalkoxybenzoyl-benzofuranes ou benzothiophenes, leur procede de preparation et les compositions les contenant
CA2384433A1 (en) Novel betulinic acid derivatives having antiangiogenic activity, processes for producing such derivatives and their use for treating tumor associated angiogenesis
PL347096A1 (en) Substituted 1,3-diaryl-2-pyridine-2-yl-3-(pyridine-2-ylamino)-propanol derivatives, methods for their production, pharmaceutical compositions containing the same and their use
WO2001009122A3 (en) Serotonergic benzofurans
WO2000026399A3 (de) Verfahren zur herstellung von quercetin- und isoquercetin-derivaten

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000947850

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 505898

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref document number: 2376891

Country of ref document: CA

Ref country code: CA

Ref document number: 2376891

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 10018928

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000947850

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 200207338

Country of ref document: ZA

WWW Wipo information: withdrawn in national office

Ref document number: 2000947850

Country of ref document: EP